Phathom Pharmaceuticals (PHAT) Current Assets (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has reported Current Assets for 9 consecutive years, with $295.9 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Current Assets rose 35.2% year-over-year to $295.9 million; the TTM figure through Jun 2026 stood at $295.9 million (up 35.2% YoY), while the FY2025 annual figure was $229.0 million, down 36.42% from the prior year.
• Current Assets rose to $295.9 million in Q2 2026 per PHAT's latest filing, from $276.6 million in the prior quarter.
• Across five years, Current Assets topped out at $397.4 million in Q4 2023 and bottomed at $139.8 million in Q1 2023.
• Historically, Current Assets has averaged $256.0 million across 5 years, with a median of $243.3 million in 2023.
• Annual changes were most pronounced in 2023 — Current Assets soared 147.6% — and 2025, when it slumped 44.42%.
• Phathom Pharmaceuticals' Current Assets stood at $160.5 million in 2022, then surged by 147.6% to $397.4 million in 2023, then declined by 9.38% to $360.1 million in 2024, then plunged by 36.42% to $229.0 million in 2025, then rose by 29.24% to $295.9 million in 2026.
• Business Quant data shows PHAT's Current Assets at $295.9 million in Q2 2026, $276.6 million in Q1 2026, and $229.0 million in Q4 2025.